PIK3CA
PIK3CA
Overview
PIK3CA encodes the catalytic p110α subunit of class I phosphoinositide 3-kinase (PIK3CA), a central signaling enzyme in pathways that regulate cell growth, survival, metabolism, and proliferation. As a protein target, PIK3CA is especially important in oncology because activating mutations can drive aberrant PI3K/AKT signaling and contribute to tumor progression and therapy resistance.
In biomedical research, PIK3CA is frequently studied as a drug target for selective PIK3CA inhibition. This is particularly relevant in cancers such as cervical cancer and breast cancer, where mutant PIK3CA can create a dependency on PIK3CA signaling. Recent studies also place PIK3CA within broader pathway networks involving EGFR/SRC-mediated EMT, KRAS, MAPK1, PTGS2, and the PI3K/Akt signaling pathway, underscoring its role as a hub in oncogenic signaling.
Recent Publications Focus
Below is a summary of the newest research publications targeting PIK3CA (sorted by publication date).
Recent studies have established PIK3CA mutations as significant drivers of cancer immunogenicity and predictors of therapeutic response. In urothelial carcinoma, PIK3CA mutations were enriched in responders to immune checkpoint inhibitors, and functional studies demonstrated that PIK3CA mutations enhance tumor immunogenicity through activation of the IRF1-NLRC5-MHC-I axis [42413983]. PIK3CA-mutant tumor cells showed enhanced cytotoxicity when co-cultured with immune cells and anti-PD-L1 antibodies, an effect dependent on PIK3CA, as PIK3CA knockdown abolished this enhancement and reduced pro-inflammatory cytokines and CD8+ effector molecules [42413983]. Similar therapeutic vulnerabilities have been observed across other malignancies: PIK3CA-mutant cervical cancer showed selective suppression with PI3Kα-specific inhibitors alpelisib and inavolisib, with combined treatment alongside antigen-specific T-cell therapy producing enhanced tumor cell killing [41980433]. In breast cancer, phosphoproteomic profiling of PIK3CA hotspot mutants (E545K and H1047R) revealed mutation-specific signaling architectures and differential responses to PI3Kα inhibition, with evidence supporting dual targeting of PI3K and MAPK pathways for improved therapeutic efficacy [42204977].
PIK3CA has been implicated in regulating multiple oncogenic phenotypes beyond cell proliferation. In non-small cell lung cancer, TRERNA1-mediated suppression of ferroptosis was mechanistically linked to PIK3CA through a KAT6A/H3K23ac/TRIM24-PIK3CA regulatory pathway, with PIK3CA overexpression rescuing ferroptosis suppression [42340519]. Network pharmacology and molecular docking studies have identified natural bioactive compounds with predicted or confirmed activity against PIK3CA, including psoralen from Trigonostemon xyphophyllorides, which demonstrated potent antiproliferative effects in renal cell carcinoma through PI3K/AKT pathway inhibition with strong binding affinity to PIK3CA [41929235], and metabolites from Clerodendrum species and sanguinarine derivatives, which network analysis predicts target PIK3CA as a central regulatory hub in oncogenic signaling pathways [42235855, 41844053]. These studies extend the characterized roles of PIK3CA beyond canonical growth signaling to encompass immune regulation, ferroptosis suppression, and metabolic control in cancer development and progression.
Emerging clinical applications for PIK3CA include precision diagnostics and personalized risk assessment. The RECO-Cas assay enables highly sensitive (90.48%) and specific (100%) detection of PIK3CA point mutations in cell-free DNA from plasma samples, supporting early cancer diagnosis and personalized treatment selection [42172311]. Beyond malignancy, germline and somatic PIK3CA variants have clinical significance in overgrowth syndromes: CLOVES syndrome, caused by mosaic gain-of-function PIK3CA variants such as p.Glu545Ala, can present with vascular complications including renal vein thrombosis, identified as a potentially reversible cause of acute kidney injury in affected patients [42334730]. Environmental exposures may also dysregulate PIK3CA signaling; di-(2-ethylhexyl) terephthalate (DOTP), a widely used plasticizer alternative, was identified as promoting breast cancer progression by interfering with PIK3CA and other carcinogenic targets through the PI3K-Akt-mTOR pathway [41780785]. Collectively, these publications establish PIK3CA as both a critical therapeutic target for drug development and a key biomarker for predicting treatment response and clinical risk across diverse cancer types and molecular contexts.